Skip to main content
ADCES 2025 Annual Meeting Main banner
Back

On-Demand

Diabetes Across the Lifespan and the Cardiometabolic Continuum

D11 - The Incredible Incretins: Unlocking New Frontiers with Incretin-Based Therapies

Sunday, August 10, 2025
11:00 AM – 11:45 AM MT
CE/CME Hours: .75 CE
Pharmacology Hours: .75 CE

    Primary Presenter(s)

  • Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP (she/her/hers)

    Professor, Pharmacy Practice, PGY2 Ambulatory Care Residency Program Director, Clinical Pharmacist
    Midwestern University and Northwestern Medicine
    Chicago, Illinois

    Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)

    • Co-Presenter(s)

  • Diana Isaacs, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM (she/her/hers)

    Endocrine Pharmacist
    Cleveland Clinic
    University Heights, Ohio

    Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)

The session will delve into potential therapeutic advantages of incretin-based therapies in a variety of conditions, including but not limited to, Alzheimer's disease, sleep apnea, substance use disorder, depression, Parkinson's disease, psoriasis, and polycystic ovary syndrome (PCOS). We will discuss emerging evidence, promising clinical trials, and mechanisms that might explain these benefits. The presenters will examine the latest research on how incretin-based therapies can improve outcomes for patients with heart failure, metabolic dysfunction-associated steatotic liver disease, and chronic kidney disease. Attendees will gain an understanding of opportunities to integrate incretin-based therapies into treatment plans for individuals with conditions beyond diabetes and obesity.
Disclosure(s):
Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP: Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)
Diana Isaacs, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM: Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)